BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P, Ueland T. Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers 2017;22:261-7. [PMID: 27325138 DOI: 10.1080/1354750X.2016.1204003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Bouwens E, van den Berg VJ, Akkerhuis KM, Baart SJ, Caliskan K, Brugts JJ, Mouthaan H, Ramshorst JV, Germans T, Umans VAWM, Boersma E, Kardys I. Circulating Biomarkers of Cell Adhesion Predict Clinical Outcome in Patients with Chronic Heart Failure. J Clin Med 2020;9:E195. [PMID: 31936828 DOI: 10.3390/jcm9010195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Foroughi M, Mohammadi Z, Majidi Tehrani M, Bakhtiari M, Dabbagh A, Haji Molahoseini M. The Effect of Erythropoietin Administration on the Serum Level of YKL-40, pro-BNP and IL-6 in Coronary Surgery Patients. Iran J Pharm Res 2020;19:430-9. [PMID: 33680042 DOI: 10.22037/ijpr.2020.112867.13993] [Reference Citation Analysis]
3 Lee MMY, Sattar N, McMurray JJV, Packard CJ. Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. Curr Atheroscler Rep 2019;21:41. [PMID: 31350612 DOI: 10.1007/s11883-019-0800-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]